This clinical trial is focused on studying (GPP), a rare and severe skin condition characterized by widespread pustules, which are small, pus-filled blisters. The trial aims to evaluate the effectiveness and safety of a treatment called , which is administered through an intravenous infusion, meaning it is given directly into a vein. Spesolimab is being tested to see if it can help people who experience repeated flare-ups of GPP after their initial treatment with the same medication.

The purpose of the study is to assess how well spesolimab works in managing these recurrent flare-ups. Participants in the study will receive spesolimab infusions and will be monitored to see if their skin condition improves, specifically looking for a reduction in pustules. The study will also observe any side effects and how the body responds to the medication over time.

Throughout the study, participants will have regular check-ups to track their progress and ensure their safety. The trial is designed to provide valuable information on the use of spesolimab for treating GPP, potentially offering a new option for managing this challenging condition. The study does not involve a placebo, meaning all participants will receive the active treatment.